| Symbol: | NASDAQ: LSDI |
| Shares OS: | 25 million (aft 2 acq) |
| Current valuation: | HIGHLY UNDERVALUED |
| Market Cap: | Under $16million |
| Current Price: | Shares are consolidating below $1.00 as some long-term investors sold their positions **before recent news came out** |
| Float | 10 million/IPO price $4.00 |
Analyst report from Singular Research gives Lucy Scientific Discovery a BUY venture rating up to $3.50 and this DOES NOT take into consideration recently announced acquisition targets.
**Westpark** says it’s an easy 100% move from today’s price up to $1.40. **
**LSDI: announced 2 strategic acquisitions, BlueSky Wellness and High Times. According to recent press, upon the closing of the transactions, Lucy Scientific expects to have approximately 25 million shares issued and outstanding; and projects the two transactions on a consolidated basis to add a minimum of $30 million of revenue and $10 million of EBITDA for the first twelve-month period after closing.
The Company expects the acquisition of High Times IP, including, the 18 licensing agreements across various product categories it will acquire, to add at least $10M of revenue and $5M of EBITDA to its 2024 results and provide a solid foundation of growth as cannabis becomes legal around the world.
Some simplistic math: After closing 25 million shares outstanding, with 30 million in revenue and an estimated $10 million in EBITDA, at a multiple of 10 times EBITDA the company would be worth $100 million or more than 6 times its current trading price!
The Blue-Sky acquisition is expected to close in 90 days. The platform is an E-commerce platform which boasted $22 million in revenue in 2022 and adjusted EBITDA of $3 million alone.
Hold onto your hats because a storm of news is coming! Expect a whirlwind of updates ranging from acquisitions to FDA revelations, financial insights, and so much more!
» LSDI acquisition strategy consolidation news.
» Closing of Blue-Sky transaction.
» Analyst coverage and updates
» Sector news, FDA news, expansion news?
» Other possible acquisitions?
» Financial updates
(The mind medicine sector is heating up as several states have approved therapeutic uses and legalization, as well as the UPCOMING ruling of the FDA on one of the well-known drug candidates for approval of therapeutic use, PTSD etc.)
The company recently announced two acquisitions in the alternative medicines space, setting the stage for several upcoming market moving catalysts.
The stock has been consolidating in this price range for several weeks. The stock has a short position in it, and as buying continues to build pressure, short, biased traders will be forced to buy shares back from you at much higher prices.
One more reason to take a position in LSDI!
Why LSDI? Because we trust WINNERS! CEO Richard Nanula isn’t just any leader. He’s a titan who has commanded a whopping $50 billion in M&A and financing transactions! Working for companies like Disney, Amgen, and Starwood.
It’s only been a short period of time, and he’s already been involved in 2 highly beneficial transactions for Lucy Scientific Discovery, (LSDI) what’s next?
As more news comes out and the stocks begins to perk up, you will remember reading this and thinking you missed out, however, if the analysts are correct, and the company’s projects come to fruition, we could see Analysts price targets upgraded, closer to our “back of the napkin” math above.
Many stocks with a relatively small float have exceeded expectations over the past two years. Do your own research and remember you can always take profits and trade on the dips.
247MarketNews
Editor
If we learned anything over the past few years it’s that Billionaires get what they want and they’re pouring a ton of dough into Psychotropic Therapy:
Signup today for free and be the first to get notified of breaking news. You can also enter your mobile number for text message alerts!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
DISCLOSURE: 24/7 Market News Inc. (247), owns and operates www.247marketnews.com is a third-party publisher and news release service provider which disseminates corporate news electronically through multiple online media platforms. 247 is NOT an affiliate with any of the companies mentioned in our reports. 247 is a news distribution service and is not registered with FINRA or any other professional licensing service. 247 is not an analyst, broker dealer or advisor, and holds no such licenses. 247 may NOT offer to buy, sell, or hold any security. 247 Venture Beats, and Breakfast bits and any other corporate profiles will NEVER be a solicitation or recommendation of any kind, of any security mentioned. The materials in all our releases are intended to be for informational purposes only and should never be considered research or due diligence on any company mentioned. All readers are encouraged to perform standard due diligence by reading the company’s filings at SEC.gov. Readers should consult their broker or licensed professional before investing in any company. All materials in this release are based on publicly available statements made by the companies. 247 is not liable for any investment decisions made by any readers or subscribers. Any investment could result in you losing all your money from investing in any stock. 247’s editor owns no shares of $LSDI and will not trade in the stock. Publisher has been paid to write and send relevant information concerning Lucy Scientific Discovery Inc. to interested readers. 24/7 has been paid up to twenty-five thousand dollars per week by Totaligent for continuous updates and coverage over the next three months 24/7 will use also be using Totaligent’s financial marketing tools and platform. Editors are paid to put a best-case scenario profile out to the investing public. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements.
